PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Steg, Philippe Gabriel
TI  - Safety and Tolerability Darexaban in Patients with ACS: The RUBY-1 Trial
DP  - 2011 Nov 01
TA  - MD Conference Express
PG  - 13--14
VI  - 11
IP  - 10
4099  - http://mdc.sagepub.com/content/11/10/13.short
4100  - http://mdc.sagepub.com/content/11/10/13.full
AB  - Results from the RUBY-I trial [NCT00994292] showed a dose-related, 2- to 4-fold increase in bleeding when the factor Xa inhibitor darexaban was added to standard treatment (aspirin with or without clopidogrel) for the secondary prevention of ischemic vascular events in patients with recent acute coronary syndrome.